Section Review: Cardiovascular & Renal: Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases

References

• BUTCHER RW, SUTHERLAND EW: Adenosine 3',5'-phos-phate in biological materials. 1. Purification and prop-erties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phos-phate in human urine. J. Biol. Chem. (1962) 237:1244–1250.
   Google Scholar
• BEAVO JA: Multiple isozymes of cyclic nucleotide phos-phodiesterases. In: Advances in Second Messenger and Phosphoprotein Research. Greengard P, Robison GA (Eds.). Raven Press, New York (1988) 22:1–38.
   PubMedGoogle Scholar
• BEAVO JA: Multiple phosphodiesterase isoenzymes:Background, nomenclature and implications. In: Mo-lecular Pharmacology of Cell Regulation. Houslay MD (Ed.). Wiley J & Sons, Chichester (1990) 2:3–15.
   Google Scholar
• BEAVO JA, CONTI M, HEASLIP Rj: Multiple cyclic nucleo-tide phosphodiesterases. Mol. Pharmacol. (1994) 46:399–405.
   PubMed Web of Science ®Google Scholar
• Coyn M, JIN S-LC, MONACO L, REPASKE DR, SWINNEN JV: Hormonal regulation of cyclic nucleotide phos-phodiesterases. Endocrine Reviews (1991) 12:218–233.
   PubMed Web of Science ®Google Scholar
• BELTMAN J, SONNENBURG WK, BEAVO JA: The role of protein phosphorylation in the regulation of cyclic nucleotide phosphodiesterases. Mol. Cell. Biochem (1993) 127/128:239–253.
   Google Scholar
• SETTE C, VICINI E, HESS M, CONTI M: Short term activa-tion of a rolipratn-sensitive, cAMP-specific phosphodi-esterase through a cAMP-dependent phosphorylation. FASEB J. (1994) 8:A370.
   Google Scholar
• BURNS F, RODGER IW, PYNE NJ: The catalytic subunit of protein kinase A triggers activation of the type V cyclic (MP-specific phosphodiesterase from guinea-pig lung. Biochem. J. (1992) 283:487–491.
   PubMed Web of Science ®Google Scholar
• WYATT A, FRANCIS SH, MCALLISTER-LUCAS LM, NAFTILAN AJ, CORBIN JD: Phosphorylation of cGMP-binding cGMP-specific phosphodiesterase in vascular smooth muscle cells. FASEB J. (1994) 8:A372.
   Web of Science ®Google Scholar
• KISHI Y, ASHIKAGA T, WATANABE R, NUMANO F: Atrial natriuretic peptide reduces cyclic AMP by activating cyclic GMP-stimulated phosphodiesterase in vascular endothelial cells. J. Cardiovasc. Pharmacol. (1994) 24:351–357.
   PubMed Web of Science ®Google Scholar
• MACFARLAND RT, ZELUS BD, BEAVO JA: High concentra-tions of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroiclogenesis In adrenal glomerulosa cells. J. Biol. Chem. (1991) 266:136–142.
   PubMed Web of Science ®Google Scholar
• HOUSLAY MD: PDE IV subtypes: CNS distribution, rolipram inhibition and membrane association. Phos-phodiesterase Inhibitors and their Therapeutic Potential. Wil-liam Harvey Research Conferences. London, 21st - 22nd June (1995):7–8.
   Google Scholar
• CHASIN M, HARRIS DN: Inhibitors and activators of cyclic nucleotide phosphodiesterase. In: Advances in Cyclic Nucleotide Research . Greengard P, Robison GA (Eds.). Raven press, New York (1976) 7:225–264.
   PubMedGoogle Scholar
• LUGNIER C, KOMAS N: Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilation. Eur. Hear t J. (1993) 14(Suppl. I):141–148.
   Google Scholar
• LUGNIER C, GAUTHIER C, LR BEC A, SOUSTRE H: Cyclic nucleotide phosphodiesterases from frog atrial fibers: Isolation and drug sensitivities. Am. J. Physiol. (1992) 262:H654–H660.
   PubMed Web of Science ®Google Scholar
• HAGIWARA M, ENDO T, HIDAKA H: Effect of vinpocetineon cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol (1984) 33:453–457.
   PubMed Web of Science ®Google Scholar
• PODZUWEIT T, MULLER A, NENNSI1EL P: Selective inhi-bition of the cGMP-stimulated cyclic nucleotide phos-phodiesterase from pig and human myocardium. J. Mol. Cell. Cardiol. (1994) 24\(Suppl. 5):S102.
   Google Scholar
• MERY PF, PAVOINE C, PECKER F, FISCHMEISTER R: Erythro-9-(2-hydroxy-3-nony0 adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol. Ph armacol. (1995) 48:121–130.
   PubMed Web of Science ®Google Scholar
• VARGEESE C, SARMA MS, PRAGNACHRYULU PV, ABUSHA-NAB E, LI SY, STOECICLER JD: Adenosine deaminase Inhibitors. Synthesis and biological evaluation of puta-tive metabolites of (+)-erythro-9-(3S-hydroxy-3R-nonyHadenine. J. Med. Chem. (1994) 37:3844–3849.
   Google Scholar
• BRISTOL JA, SIRCAR I, MOOS WH, EVANS DB, WEISHAARRE: Cardiotonic agents. 1. 4,5-dihydro-6-[4(111-imida-zol-1-y1)-3(211)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J. Med. Chem. (1984) 27:1099–1101.
   Google Scholar
• BETHKE T, MEYER W, SCHMITZ W, SCHOLZ H, THOMASK, WENZLAFF H, ARMAH B, RAAP A, TRAUPE B: Phos-phodiesterase III inhibition by MCI-154 and other cardiotonlc drugs in relation to force of contraction, cAMP content and calcium sensitization in the heart. Eur. J. Pharmacol. (1990) 183:783–784.
   Web of Science ®Google Scholar
• BRUNKHORST D, VAN DER LEYDEN H, MEYER W, NIGBURR, SCHMIDT-SCHUMACHER C, SCHOLZ H: Relation of positive inotropic and chronotropic effects of pi-mobendan, UD-CG 212 CL, milrinone and other phos-phodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart Naunyn Schmiedeberg's Arch. Pharmacol. (1989) 339:575–583.
   Google Scholar
• HIDAKA H, HAYASHI H, KHORI H, KIMURA Y, HOSOK-AWA T, IGAWA T, SAITOH Y: Selective inhibitor of platelet cyclic adenosine monophosphate phosphodi-esterase, cilostatnide, inhibits platelet aggregation. J. Pharrnacol. Exp. Ther. (1979) 211:26–30.
   PubMed Web of Science ®Google Scholar
• LUGNIER C, STIERLE A, BERETZ A, SCHOEFFTER P, LE BEC A, WERMUTH CG, CAZENAVE JP, STOCLET JC: Tissue and substrate specificity of inhibition by alkoxy-aryl-lac-tams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases: relationship to phar-macological activity. Biochem. Biophys. Res. Commun. (1983) 113:954–959.
   PubMed Web of Science ®Google Scholar
• GILLESPIE E: Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activ-ity. Biochem. Pharmacol. (1988) 37:2866–2868.
   PubMed Web of Science ®Google Scholar
• VAN DE WATER A, XHONNEUX R, RENEMAN RS, JANSSEN PA: Cardiac and hemodynamic effects of intravenous R80122 a new phosphodiesterase M inhibitor, in a canine model of myocardial ischemia and heart failure. Cardiovasc. Pharmacol. (1992) 20:18–24.
   PubMed Web of Science ®Google Scholar
• DUNDORE RL, PAGANI ED, BODE DC, BACON ER, SINGH B, LESHER GY, BUCHOLZ RA, SILVER PJ: Species-depend-ent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase M inhibitors WIN 58993 and WIN 62005.1 Cardiovasc. Pharmacol. (1995) 25:14–21.
   Google Scholar
• RUPPERT D, WEITHMANN KU: HL 725, an extremely potent inhibitor of platelet phosphodiesterase induced platelet aggregation in vitro. Life Sci. (1982) 31:2037–2043.
   PubMed Web of Science ®Google Scholar
• LUGNIER C, SCHINI V: Characterization of cyclic nucleo-tide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem. Pharmacol. (1990) 39:75–84.
   PubMed Web of Science ®Google Scholar
• SEILER S, GILLESPIE E, ARNOLD AJ, BRASSARD CL, MEAN-WELL NA, FLEMING JS: Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase In platelets. Thromb. Res. (1991) 62:31–42.
   PubMed Web of Science ®Google Scholar
• TORPHY TJ, STADEL JM, BURMAN M, CIESLINSKI LB, MCLAUGHLIN MM, WHITE JR, uvt GP: Co-expression of human cAMP-specific phosphodiesterase activity andhigh affinity rolipram binding in yeast J. Biol. Chem. (1992) 267:1798–1804.
   Web of Science ®Google Scholar
• WATSON J: Can nausea induced by PDE W inhibitors beovercome? Phosphodiesterase Inhibitors and their Therapeu-tic Potential. William Harvey Research Conferences. London, 21st - 22nd June (1995).
   Google Scholar
• SCHULTZ G, HARDMAN JG, SCHULTZ K, DAVIS JW, SUTH-ERLAND EW: A new enzymatic assay for guanosine 3', 5' cyclic monophosphate and its application to the ductus deferens of the rat Proc. Natl. Acad. Sci. USA (1973) 70:1721–1725.
   PubMed Web of Science ®Google Scholar
• HEASLIP RJ, LOMBARDO LJ, GOLANKIEWICZ JM, ILSE-MANN BA, EVANS DY, SICKELS BD, MUDRICK JF, BAGLI J, WEICHMAN BM: Phosphodiesterase IV inhibition, respi-ratory muscle relaxation and bronchodllatation by WAY-PDA-641. J. Pharmacol. Exp. Ther. (1994) 268:888–896.
   PubMed Web of Science ®Google Scholar
• RAEBURN D, UNDERWOOD SL, LEWIS SA, WOODMAN VR, BATIRAM CH, TOMKINSON A, SHARMA S, JORDAN R, SOUNESS JE, WEBBER SE, 'CARLSSON JA: Anti-inflamma-tory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibition. Br. Pharmacol. (1994) 113:1423–1431.
   PubMed Web of Science ®Google Scholar
• HIGGS G: The development of a PDE IV inhibitor for the treatment of bronchial asthma. Phosphodiesterase Inand their Therapeutic Potential. William Harvey Research Conferences. London, 21st - 22nd June (1995):23.
   Google Scholar
• MULLER B, LUGNIER C, STOCLET J-C: Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction. J. Cardiovasc. Pharmacol. (1990) 16:796–803.
   PubMed Web of Science ®Google Scholar
• SHAHID M, NICHOLSON CD: Comparison of cyclic nu-cleotide phosphodiesterase isoenzymes in rat and rab-bit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, mil-rinone and rolipram. Naunyn Schmiedeberg's Arch. Phar-macol. (1990) 342:698–705.
   Google Scholar
• SCHUDT C, WINDERS, MULLER B, UKENA D: Zardaverine as selective inhibitor of phosphodiesterase isoen-zymes. Biochem. Pharmacol (1991) 42:153–162.
   PubMed Web of Science ®Google Scholar
• LUGNIER C, SCHOEFF lER P, LE BEC A, STROUTHOU E, STOCLET JC: Selective inhibition of cyclic nucleotide phosphodiesterase of human, bovine and rat aorta. Biochem. Pharmacol. (1986) 35:1743–1751.
   PubMed Web of Science ®Google Scholar
• HAGIWARA M, ENDO T, KANAYAMA T, HIDAICA H: Effect of 1-(3-chloroanilino)-4-phenylphtalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation. J. Pharmacol. Exp. Ther. (1984) 228:467–471.
   PubMed Web of Science ®Google Scholar
• KODAMA K, ADACHI H, MORI N, SAITO I: Effects of a novel, selective and potent phosphodiesterase type V, Inhibitor E 4021, on myocardial ischetnia in guinea-pigs. Eur. J. Pharmacol . (1994) 263:93–99.
   PubMed Web of Science ®Google Scholar
• COSTE H, GRONDIN P: Characterization of a novel potent and specific inhibitor of type V phosphodi-esterase. J. Cardiovasc. Pharmacol. (In press).
   Google Scholar
• THOMPSON WJ, EPSTEIN PM, STRADA SJ: Purification and characterization of high affinity cyclic adenosine mo-nophosphate phosphodiesterase from dog kidney. Bio-chemistry (1979) 18:5228–5237.
   Google Scholar
• WELLS JN, HARDMAN JG: Cyclic nucleotide phosphodi-esterases. In: Advances in Cyclic Nucleotide Research. Greengard P, Robison GA (Eds.). Raven Press, New York (1977) 8:119–143.
   PubMedGoogle Scholar
• TANIGUCHI T, FUJIWARA M, LEE JJ, HIDAKA H: Cyclic3':5'-nucleotide phosphodiesterase of rabbit sinoatrial node. Biochim. Biophys. Acta (1978) 522:465–476.
   PubMed Web of Science ®Google Scholar
• HARRISON SA, REIFSNYDER DH, GALLIS B, CADD GG, BEAVO JA: Isolation and characterization of bovine cardiac musde cGMP-inhibited phosphodiesterase : a receptor for new cardiotonic drugs. Mol. Pharmacol. (1986) 29:506–514.
   PubMed Web of Science ®Google Scholar
• KOMAS N, LUGNIER C, LE BEC A, SERRADEIL-LE GAL C,BARTHELEMY G, STOCLET JC: Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases Isolated from canine ventricular and sinoatrial-en-riched tissues. J. Cardiovasc. Pharmacol. (1989) 14:213–220.
   PubMed Web of Science ®Google Scholar
• REEVES ML, LEIGH BK, ENGLANG PJ: The identificationof a new cyclic nucleotide phosphodiesterase activity In human and guinea-pig cardiac ventricle. Biochem. J. (1987) 241:535–541.
   PubMed Web of Science ®Google Scholar
• TENOR H, BARTEL S, KRAUSE EG: Cyclic nucleotide phosphodiesterase activity in the rat myocardium: evi-dence of four different PDE subtypes. Biomed. Biochim. Acta (1987) 46:S749–753.
   Google Scholar
• NICHOLSON CD, CHALLISS RAJ, SHAHID M: Differentialmodulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodi-esterase isoenzymes. Trends. Pharmacol. Sci. (1991) 12:19–27.
   PubMed Web of Science ®Google Scholar
• MASUOKA H, ITO M, NAKANO T, NAKA M, TANAKA T:Effects of amrinone and enoximone on the subclasses of cyclic AMP phosphodiesterase from human heart and kidney. J. Cardiovasc. Pharmacol. (1990) 15:302–307.
   PubMed Web of Science ®Google Scholar
• MASUOKA H, ITO M, SUGIOICA M, KOZEKI H, KONISHI T,TANAKA T, NAKANO T: Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent. Biochem. Biopbys. Res. Commun. (1993) 190:412–417.
   PubMed Web of Science ®Google Scholar
• LUGNIER C, MULLER B, LE BEC A, BEAUDRY C, ROUSSEAUE: Characterization of indolidan- and rolipram-sensi-tive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J. Pharmacol. Exp. 7ber. (1993) 265:1142–1151.
   Google Scholar
• PRIGENT AF, FOUGIER S, NEMOZ G, ANKER G, PACHECOH, LUGNIER C, LE BEC A, STOCLET JC: Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta: separation and inhibition by selective inhibitors. Biochem. Pharmacol. (1988) 37:3671–3681.
   PubMed Web of Science ®Google Scholar
• MULLER B, STOCLET JC, LUGNIER C: Cytosolic and mem-brane-bound cyclic nucleotide phosphodiesterases from guinea pig cardiac ventricles. Eur. J. Pharmacol. - Mol. Pharmacol. Sect. (1992) 225:263–272.
   PubMed Web of Science ®Google Scholar
• KOMAS N, LE BEC A, STOCLET JC, LUGNIER C: CardiaccGMP-stimulated cyclic nucleotide phosphodi-esterases: effects of cGMP analogues and drugs. Eur. J. Pharmacol. (1991) 206:5–13.
   PubMed Web of Science ®Google Scholar
• TIMOUYASSE L, PRIGENT AF, NEMOZ G, LAGARDE M, PACHECO H: Differential susceptibility to biological detergents of the particulate cGMP-stimulated phos-phodiesterase from rat heart: preservation of the altos-teric properties of the solubilized enzyme. Biochem. Int. (1989) 19:287–299.
   PubMedGoogle Scholar
• KOMAS N, LUGNIER C, STOCLET JC: Pharmacological characterization of membrane-bound forms of cAMP phosphodiesterase from cardiac tissues. J. Mol. Cell Cordial. (1990) 22\(Suppl. 4):S32.
   Google Scholar
• WEISHAAR RE, KOBYLARZ-SINGER DC, STEFFEN RP, KAPLAN HR: Subclasses of cyclic AMP-specific phos-phodiesterase in left ventricular muscle and their in-volvement in regulating myocardial contractility. Circ. Res. (1987) 61:539–547.
   PubMed Web of Science ®Google Scholar
• SMITH CJ, KRALL J, MANGANIELLO VC, MOVSESIAN M: Cytosolic and sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mam-malian myocardium. Biochem. Biopbys. Res. Commun. (1993) 190:516–521.
   PubMed Web of Science ®Google Scholar
• MEACCI E, TAIRA M, MOOS M, Jr., SMITH CJ, MOVSESIAN M, DEGERMAN E, BELFRAGE P, MANGANIELLO V: Molecu-lar cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc. Natl. Acad. Sci. USA (1992) 89:3721–3725.
   PubMed Web of Science ®Google Scholar
• TAIRA M, HOCKMAN SC, CALVO JC, TAIRA M, BELFRAGEP, MANGANIELLO VC: Molecular cloning of the rat adipo-cyte hormone-sensitive cyclic GMP-inhibited cyclic nu-cleotide phosphodiesterase. J. Biol. Chem. (1993) 268:18573–18579.
   PubMed Web of Science ®Google Scholar
• MURATA T, TAIRA M, MANGANIELLO VC: Structure/func-tion analysis of recombinant type III cGMP-inhibited cyclic nucleotide phosphodiesterase (PDE3): Use of N-terminal region deletion recombinants to study PDE3 membrane-association. FASEB J. (1995) 9:A1262.
   Web of Science ®Google Scholar
• WEISHAAR RE, BURROWS SD, KOBYLARZ DC, QUADE MM, EVANS DB: Multiple molecular forms of cyclic nucleo-tide phosphodiesterase in cardiac and smooth muse_k and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem. Pharmacol, (1986) 35:787–800.
   Google Scholar
• KOMAS N, LUGNIER C, STOCLET JC: Endothelium-de-pendent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br. J. Pharmacol. (1991) 104:495–503.
   PubMed Web of Science ®Google Scholar
• KOMAS N, LUGNIER C, ANDRIANTSITOHAINA R, STOCLETJC: Characterization of cyclic nucleotide phosphodi-esterases from rat mesenteric artery. Eur. j Pharmacol. - Mol. Pharmacol. Sect. (1991) 208:85–87.
   PubMed Web of Science ®Google Scholar
• IVORRA DM, LE BEC A, LUGNIER C: Characterization ofmembrane-bound cyclic nucleotide phosphodi-esterases from bovine aortic smooth muscle. J. Cardiovasc. Pharmacol. (1992) 19:532–540.
   PubMedGoogle Scholar
• KISHI Y, ASHIKAGA T, NUMANO F: PhosphodiesterasesIn vascular endothelial cells. I= Advances in Second Messenger and Phosphoprotein Research. Greengard P, Ro-bison GA (Eds.). Raven Press, New York (1992) 25:201–213.
   PubMedGoogle Scholar
• KAUFFMAN RF, SCHENCK KW, UTTERBACK BG, CROWEVG, COHEN ML: In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase Inhibition and cyclic nucleotides./ Pharmacol. Exp. Ther. (1987) 242:864–872.
   PubMed Web of Science ®Google Scholar
• LINDGREN S, RASCON A, ANDERSSON K-E, MANGANIELLOV, DEGERMAN E: Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodi- esterases and relaxation of rat aorta. Biochem. Pharma-col. (1991) 42:545–552.
   PubMed Web of Science ®Google Scholar
• LINDGREN S, ANDERSSON K-E, BELFRAGE P, DEGERMAN E, MANGANIELLO VC: Relaxant effects of the selective phosphodiesterase inhibitors mikinone and OPC 3911 on isolated human mesenteric vessels. Pharmacol. Taxi-col. (1989) 64:440–445.
   PubMedGoogle Scholar
• SOUNESS JE, DIOCEE BK, MARTIN W, MOODIE SA: Pig aortic endothelial cell cyclic nucleotide phosphodi-esterases: use of phosphodiesterase inhibitors to evalu-ate their roles in regulating cyclic nucleotide levels in Intact cells. Biochem. J. (1990) 266:127–132.
   PubMed Web of Science ®Google Scholar
• TANI T, SAKURAI K, KIMURA Y, ISHIKAWA T, HIDAKA H: Pharmacological manipulation of tissue cyclic AMP by Inhibitors: Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. In: Advances in Second Messenger and Phosphoprotein Re-search. Greengard P, Robison GA (Eds.). Raven Press, New York (1992) 25:215–227.
   PubMedGoogle Scholar
• ASHIKAGA T, STRADA SJ, THOMPSON 'OVJ: Altered expres-sion of bovine aortic endothelial cell (BAEC) cyclic nucleotide (CN) phosphodiesterase (POE) isozymes during culture. FASEB J. (1993) 7:759.
   Google Scholar
• HIDAKA H, ASANO T: Human blood platelet 3':5'-cyclic nucleotide phosphodiesterase. Biochim. Biophys. Acta (1976) 429:485–497.
   PubMed Web of Science ®Google Scholar
• GRANT PG, MANNARINO AF, COLMAN RW: cAMP-medi-ated phosphorylation of the low-Km cAMP phosphodi-esterase markedly stimulates its catalytic activity. Proc. Natl. Acad. USA (1988) 85:9071–9075.
   PubMed Web of Science ®Google Scholar
• MACPHEE CH, HARRISON SA, BEAVO JA: Immunologicalidentification of the major platelet low-Km cAMP phos-phodiesterase: Probable target for anti-thrombotic agents. Proc. Natl. Acad. Sci. USA (1986) 83:6660–6663.
   PubMed Web of Science ®Google Scholar
• MACPBEE CH, REIFSNYDER DH, MOORE TA, LEVEA KM,BEAVO JA: Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. J. Biol. Chem (1988) 263:10353–10358.
   PubMed Web of Science ®Google Scholar
• ASHIDA S-I, SAKUMA K: Demonstration of functionalcompartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors. In: Advances in Second Messenger Phosphoprotein Research. Greengard P, Robison GA (Eds.). Raven Press, New York (1992) 25:229–239.
   PubMedGoogle Scholar
• TSIEN WH, SASS SP, SHEPPARD H: The lack of correlationbetween inhibition of aggregation and cAMP levels in canine platelets. Thromb. Res. (1982) 28:509–519.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO S: Functional pool of cyclic adenosine3',5'-monophosphate in rabbit platelets. Thromb. Haemost. (1983) 49:8–12.
   PubMed Web of Science ®Google Scholar
• SAITOH Y, HARDMAN JG, WELLS JN: Differences in theassociation of calmodulin with cyclic nucleotide phos-phodiesterase in relaxed and contracted arterial strips. Biochemistry (1985) 24:1613–1618.
   PubMed Web of Science ®Google Scholar
• AHN HS, CRIM W, ROMANO M, SYBERTZ E, PITTS B: Effects of selective inhibitors on cyclic nucleotide phos-phodiesterases of rabbit aorta_ Biochern. Pharmacol (1989) 38:3331–3339.
   Web of Science ®Google Scholar
• HARTZELL CH, FISCHMEISTER R: Opposite effects of cy-clic GMP and cyclic AMP on Ca2+ current in single heart cells. Nature (1986) 323:273–275.
   PubMed Web of Science ®Google Scholar
• MULLER B, LUGNIER C, STOCLET JC: Implication of cyclicAMP in the positive inotropic effects of cyclic GMP-in-hibited cyclic AMP phosphodiesterase inhllAtors on guinea pig isolated left atria. J. Cardiovasc. Pharmacol. (1990) 15:444–451.
   PubMed Web of Science ®Google Scholar
• MERY PF, PAVOINE C, BELHASSEN L, PECKER F, FISCHMEISTER R: Nitric oxide regulates cardiac Ca2+ current: involvement of cGMP-inhibited and cGXP-stimulated phosphodiesterases through guanylyl cy-clase activation. J. Biol. Chem. (1993) 268:26286–26295.
   PubMed Web of Science ®Google Scholar
• REEVES ML, ENGLAND PJ: Cardiac phosphodiesterases and the functional effects of selective inhibition. In: Molecular Pharmacology of Cell Regulation. Houslay MD (Ed.). Wiley J & Sons, Chichester (1990) 2:299–316.
   Google Scholar
• FISCHER TA, ERBEL R, TREESE N: Current status of phos-phodiesterase inhibitors in the treatment of congestive heart failure. Drugs (1992) 44:928–945.
   PubMed Web of Science ®Google Scholar
• CRLTICKSHANK JM: Phosphodlesterase III inhibitors: long-term risks and short-term benefits. Cardiovasc. Drugs Ther. (1993) 7:655–660.
   PubMed Web of Science ®Google Scholar
• HALL IP: Lsoenzyme selective phosphodiesterase inhibi-tors: potential clinical uses. Br. J. Clin. Pharmac. (1993) 35:1–7.
   PubMed Web of Science ®Google Scholar
• FELDMAN AM, BRISTOW MR, PARMLEY WW, CARSON PE,PEPINE g, GILBERT EM, STROBECK JE, HENDRIX GH, POWERS ER, BAIN RP: Effects of vesnarinone on morbid-ity and mortality in patients with heart failure. New Engl. J. Med. (1993) 329:149–155.
   PubMed Web of Science ®Google Scholar
• KUBO SP, RECTOR TS, STROBECK JE, COHN JN: OPC-8212 In the treatment of congestive heart failure: results of a pilot study. Cardiovasc. Drugs Therapy (1988) 2:653–660.
   PubMed Web of Science ®Google Scholar
• MAURICE DH, HASLAM RJ: Molecular basis of the syner-gistic inhibition of platelet function by nitrovasodila-tors and activators of adenylate cyc.bse inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol. (1990) 37:671–681.
   Google Scholar
• ANDERSSON TLG, VINGE E: Interactions between iso-prenaline, sodium nitroprusside, and isozyme-selec-tive phosphodiesterase inhibitors on ADP-induced aggregation and cyclic nucleotide levels in human platelets. J. Cardiovasc. Pharmacol. (1991) 18:237–242.
   PubMed Web of Science ®Google Scholar
• ECKLY AE, LUGNIER C: Role of phosphodiesterases and Win the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br. J. Pharmacol. (1994) 113: 445–450.
   PubMed Web of Science ®Google Scholar
• MAURICE DH, HASLAM RJ: Nitroprusside enhances iso-prenaline-induced increases in cAMP in rat aortic smooth muscle. Eur. J. Pharmacol. (1990) 191:471–475.
   PubMed Web of Science ®Google Scholar
• MAURICE DH, CRANKSHAW D, HASLAM RJ: Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur.j Pharmacol. (1991) 192:235–242.
   PubMed Web of Science ®Google Scholar
• EIGENTHALER M, NOLTE C, HALBROGGE M, WALTER U:Concentration and regulation of cyclic nucleotides, cyclic nucleotide-dependent protein kinases and one of their major substrates in human platelets. Eur. J. Bio-chem. (1992) 205:471–481.
   Web of Science ®Google Scholar
• KESSLER T, LUGNIER C: Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells. Bur.]. Pharmacol. - Mol. Pharmacol. Sect. (1995) 290:163–167.
   Web of Science ®Google Scholar
• MARTIN W, EURCHGOTT RF, VILLANI GM, JOTHIANAN-DAN D: Phosphodiesterase inhibitors induce endothe-lium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released en-dothelium-derived relaxing factor. J Pharmacol. Exp. Ther. (1986) 237:539–547.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, BRADZLL R, DICEE BK, JORDAN R: Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant action of M&B 22,948, MY-5445, vin-pocetine and 1-methyl-3-isobuty1-8-(methylamino) xanthine. Br. J. Pharmacol. (1989) 98:725–734.
   PubMed Web of Science ®Google Scholar
• WEISHAAR RE, KOBYLARZ-SINGER DC, KEISER J, HALEEN SJ, MAJOR TC, RAPUNDALO S, PETERSON JT, PANEK R: Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of atrial natri-uretic factor. Hypertension (1990) 15:528–540.
   PubMed Web of Science ®Google Scholar
• TRAPANI AJ, SMITS GJ, MCGRAW DE, MCMAHON EG, BLAINE EH: Hemodynamic basis for the depressor ac-tivity of zaprinast, a selective cyclic GMP phosphodi-esterase inhibitor. J. Pharmacol. Exp. Ther. (1991) 258:269–274.
   PubMed Web of Science ®Google Scholar
• LEE KC, CANNIFF PC, HAMEL DW, PAGANI ED, GORCYZCA WP, EZRIN AM, SILVER PJ: Comparative hemodynamic and renal effects of the low Km cGMP phosphodi-esterase inhibitors cicletardne and zaprinast in anes-thetized dogs. Drug Dee. Res. (1991) 23:127–144.
   Web of Science ®Google Scholar
• MURRAY KJ, ENGLANG PJ: Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents. Biochem. Soc. Trans. (1992) 20:460–464.
   PubMed Web of Science ®Google Scholar
• RADOMSKI MW, PALMER RJ, MONCADA S: Modulation of platelet aggregation by an L-arginine-nitric oxide path-way. Trends Pharmacol. Sci. (1991) 12:87–88.
   PubMed Web of Science ®Google Scholar
• SANE DC, BIELAWSKA A, GREENBERG CS, HANNUN YA: Cyclic GMP analogs inhibit gamma thrombin-induced arachidonic acid release in human platelets. Biochem. Biophys. Res. Commun. (1989) 165:708–714.
   PubMed Web of Science ®Google Scholar
• TOUQUI L, ROTHUT B, SHAW AM, FRADIN A, VARGAFTIG BB, RUSSO-MARIE F: Platelet activation-a role for a 40 K anti-phospholipase A2 protein indistinguishable from lipocortin. Nature (1986) 321:177–180.
   PubMed Web of Science ®Google Scholar
• MATSUOKA I, NAKAHATA N, NAKANISHI H: Inhibitory effect of 8-bromo cyclic GMP on an extracelhilar Ca2+-dependent arachidonic acid liberation in collagen-stimulated rabbit platelets. Biochem. Pharmacol. (1989) 38:1841–1847.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA S, HATTORI H, SHIRATO L, TAKENAKA A, NOZAWA Y: Differential sensitivity of arachidonic acid release and 1,2-diacylglycerol formation to pertussis toxin, GDPOS and NaF in saponin-permeabilized hu-man platelets: possible evidence for distinct GTP-bind-ing proteins involving phospholipase C and A2 activation. Biochem. Biophys. Res. Commun. (1987) 148:971–978.
   PubMed Web of Science ®Google Scholar
• FRANCIS SM, CORBIN JD: Structure and function of cyclic nucleotide-dependent protein kinases. Ann. Rev. Physiol. (1994) 56:237–272.
   PubMed Web of Science ®Google Scholar
• BIEL M, ALTENHOFEN W, HULLIN R, LUDWIG J, FREICHEL M, FLOCKERZIN V, DASCAL N, KAUPP B, HOFMANN F: Primary structure and functional expression of a cyclic nucleotide-gated channel from rabbit aorta. FEBS Lett. (1993) 329:134–138.
   PubMed Web of Science ®Google Scholar
• TRAUTWEIN W, HESCHELER J: Regulation of cardiac L-type calcium current by phosphorylation and G pro-teins. Ann. Rev. Physiol. (1990) 52:257–274.
   PubMed Web of Science ®Google Scholar
• ROBINSON-STEYNER AM, CORBIN JD : Protein phospho-rylation in the heart In: The Heart and Cardiovascular System (Second Edition). Fozzard HA, Haber E, Jennings RB, Katz A, Morgan HE (Eds.). Raven Press, New-York (1992).
   Google Scholar
• HAYNES J, Jr., ROBINSON J, SAUNDERS L, TAYLOR AE, STRADA SJ: Role of cAMP-dependent protein kinase in cAMP-mediated vasodilatation. Am. J. Physiol. (1992) 262:H511–H516.
   PubMed Web of Science ®Google Scholar
• OUEDRAOGO S, STOCLET JC, BUCHER B: Effects of cyclic AMP analogues on neurogenic transmission in the rat tail artery. Br. J. Pharmacol. (1994) 111:625–631.
   PubMed Web of Science ®Google Scholar
• LINCOLN TM, CORNWELL TL: Intracellular cyclic GMP receptor proteins. EASES J. (1993) 7:328–338.
   Google Scholar
• LINCOLN TM, KOMALAVILAS P, CORNWELL TL: Pleiot-ropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension (1994) 23:141–147.
   Google Scholar
• ECKLY AE, STOCLET JC, LUGNIER C: Involvement of protein kinase Gin vascular relaxation induced by the cyclic nucleotide phosphodiesterase IV inhibitor, rolipram. Br. J. Pharmacol. (1995) 114:206P.
   Web of Science ®Google Scholar
• JIANG H, COLBRAN JL, FRANCIS SH, CORBIN JD: Direct evidence for cross-activation of cGMP-dependent pro-tein kinase by cAMP in pig coronary arteries. J. Biol. Chem. (1992) 267:1015–1019.
   PubMed Web of Science ®Google Scholar
• OUEDRAOGO S, TSCH6PL M, STOCLET JC, BUCHER B: Effects of cyclic GMP analogues on neurogenic trans-mission in the rat tail artery. Br. J. Pharmacol. (1994) 112:867–872.
   PubMedGoogle Scholar
• SCHMIDT HHHW, LOHMAN SM, WALTER U: The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim. Biophys. Acta (1993) 1178:153–175.
   PubMed Web of Science ®Google Scholar
• PACKER M: A novel approach to the development of positive inotropic agents for chronic heart failure. J. Cardiovasc. Pharmacol. (1995) 26\(Suppl. 1):S52–S56.
   Google Scholar
• GOLDBERG AD, GOLSTEIN S, NICKLAS J: Multicenter trial of imazodan in patient with chronic congestive heart failure. Circulation (1990) 82\(Suppl. 3)111673.
   Google Scholar
• URETSKY BE, JESSUP M, KONSTAM MA, DEC GW, LEIER CV, BENOTTI J, MURALI S, HERRMANN HC, SANDBERG JA: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo. Circulation (1990) 82:774–780.
   PubMed Web of Science ®Google Scholar
• PACKER M, CARVER JR, RODEHEFFER RJ, IVANHOE RJ, DIBIANCO R, ZELDIS SM, HENDRIX GH, BOMMER WJ, ELKAYAM U, KUKIN ML: Effect of milrinone on mortality in severe chronic heart failure. New Engl. J. Med. (1991) 325:1468–1475.
   PubMed Web of Science ®Google Scholar
• NONY P, BOISSEL JP, LIEVRE M, LEIZORIVICZ A, HAUGH MC, FAREH, DE BREYNE B: Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur. j Clin. Pharmacol. (1994) 45:191–196.
   Google Scholar
• SWEET CS, LUDDEN CT, STABILTTO II, EMMERT SE, HEYSE JF: Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial in-farction. Eur. J. Pharmacol. (1988) 147:29–37.
   PubMed Web of Science ®Google Scholar
• SCHEMAN MM, FOR ENOXIMONE STUDY GROUP: Dou-ble-blind, placebo-controlled 12 week trial of low dose enoximone in patients with mild to moderate conges-tive heart failure. Circulation (1991) 84\(Suppl. 2):1I–243.
   Google Scholar
• KUBO SH, GOLLUB S, BOURGE R, RAHKO P, COBB F, JESSUP M, BROZENA S, BRODSKY M, KIRLIN P, SHANES J: For the Pimobendan Multicenter Research Group. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure results of a multicenter triaL Circulation (1992) 85:942–949.
   Google Scholar
• BERGMAN MR, LEE HC, HOLYCROSS BJ: The effect of phosphodiesterase inhibitors on myocardial cytokine production. FASEB J. (1995) 9:A932.
   Web of Science ®Google Scholar
• HASHIMOTO K, MITSUHASHI H: Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhytharias. Br. J. Pharmacol. (1986) 88:915–921.
   PubMed Web of Science ®Google Scholar
• FELDMAN AM, BAUGHMAN KL, LEE WK, GoTruEs SH, WEISS JL, BECKER LC, STROBECK JE: Usefulness of OPC-8212, a quinolone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy. Am.J. Cardiol. (1991) 68:1203–1210.
   PubMed Web of Science ®Google Scholar
• CALDERONE C, KRUICENKAMP TB, BURNS PG, MISARE BD, GAUDETTE GR, LEVITSY S: Ischernia-dependent efficacy of phosphodiesterase inhibition- Ann. Thorac. Surg. (1994) 57:540–545.
   Google Scholar
• EDDY LJ, GOEDDEL DV, WONG GHW: Tumor necrosis factor-a pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem. Bio-phys. Res. Commun. (1992) 184:1056–1059.
   PubMed Web of Science ®Google Scholar
• BORCHERT G, BARTEL S, BEYERDöRFER I, KeTTNER I, SZEKERES L, KRAUSE EG: Long lasting anti-adrenergk effect of 7-oxo-prostacydin in the heart: a cyclohexi-mide sensitive increase of phosphodiesterase isoform I and IV activities. Mol. Cell. Biochem. (1994) 132:57–67.
   PubMedGoogle Scholar
• SZEKERES L, SZILVASSY Z, UVARY E, VEGH E: 7-oxo-PGI, induced late appearing and long lasting electrophysi-°logical changes in the heart in situ of the rabbit, guinea-pig, dog and cat. J. Mol. Cell. Cardiol. (1989) 21:545–554.
   PubMed Web of Science ®Google Scholar
• SIMPSON PJ, SCHELM JA, SMALLWOOD JF, CLAY MP, LINDSTROM TD: Inhibition of granulocyte cAMP-phos-phodiesterase by rolipratn in vivo is not sufficient to protect the canine myocardiurn from reperfusion in-jury. J. Cardiovasc. Pharmacol. (1995) 19:987–995.
   Google Scholar
• KATO H, ARAKI T, ITOYA Y, KOGURE K: Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, re-duces neuronal damage following cerebral ischemia in the gerbiL Eur. J. Pharmacol. (1995) 1:107–110.
   Google Scholar
• TORPHY TJ, UNDEM BJ: Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax (1991) 46:512–523.
   PubMed Web of Science ®Google Scholar
• SCHADE FU, SCHUDT C: The specific type ID and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur. Pharmacol. (1993) 230:9–14.
   PubMed Web of Science ®Google Scholar
• TURNER NC, WOOD U, BURNS FM, GUEREMY T, SOUNESS JE: The effect of cyclic AMP and cyclic GMP phosphodi-esterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages. Br. J. Pharmacol. (1993) 108:876–883.
   PubMed Web of Science ®Google Scholar
• DENT G, GIEMBYCZ MA, BABE KF, BARNES PJ: Inhibition of eosinophil cyclic nucleotide PDE activity and opson-ized zymosan-stimulated respiratory burst by 'type IV' selective POE inhibitors. Br. J. Pharmacol. (1991) 103:1339–1346.
   PubMed Web of Science ®Google Scholar
• TEIXEIRA MM, ROSSI AG, WILLIAMS TJ, HETI PWELL PG: Effect of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in guinea-pig. Br. J. Pharmacol. (1994) 112:332–340.
   PubMed Web of Science ®Google Scholar
• SANTING RE, OLYMULDER CG, VAN DER MOLEN K, MEURS H, ZAAGSMA Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. Eur. J. Pharmacol. (1995) 275:75–82.
   PubMed Web of Science ®Google Scholar
• TURNER CR, ESSER KM, WHEELDON EB: Therapeutic Intervention in a rat model of ARDS: IV. Phosphodi-esterase IV inhibition. Circulatory Shock (1993) 30:237–245.
   Google Scholar
• ARCHIPOFF G, BERETZ A, BARTHA K, BRISSON C, DE LA SALLE C, FROGET-LEON C, KLEIN-SOYER C, CAZENAVE JP: Role of cyclic AMP promoting the thromboresistance of human endothelial cells by enhancing thrombo-modulin and decreasing tissue factor activities. Br. J. Pharmacol. (1993) 109:18–28.
   PubMed Web of Science ®Google Scholar
• SANTELL L, LEVIN EG: Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator re-lease and inhibits secretion of plasminogen inhibitor-1 from human endothelial cells. J. Biol. Chem. (1988) 263:16802–16808.
   PubMed Web of Science ®Google Scholar
• HAAS TA, BERTOMEU MC, BASTIDA E, BUCHANAN MR: Cyclic AMP regulation of endothelial cell triacylglycerol turnover, 13-hydroxyoctadecadienoic acid (13-RODE) synthesis and endothelial thrombogenicity. Biochim. Biophys. Acta (1990) 1051:174–178.
   PubMed Web of Science ®Google Scholar
• MCLENACHAN JM, VITRA J, FISH RD, TREASURE CB, COX DA, GANZ P, SELWYN AP: Early evidence of endothelial vasodilator dysfunction at coronary branchpoints. Cir-culation (1990) 82:1169–1173.
   PubMed Web of Science ®Google Scholar
• SHINOKAWA H, FLAVAHAN NA, VANHOUrTE PM: Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in por-cine coronary arteries. Circ. Res. (1989) 65:740–753.
   PubMed Web of Science ®Google Scholar
• DOHI Y, LtJSCHER TF: Aging differentially affects direct and indirect actions of endothelin-1 in perfused mes-enteric arteries of the rat. Br. J. Pharmacol. (1990) 100:889–893.
   PubMed Web of Science ®Google Scholar
• VAN OVERLOOP B, STOCLET JC, GAIRARD A: Age, endo-thelium and aortic reactivity to calcium in Wistar rat. Life Sci. (1993) 53:821–831.
   PubMed Web of Science ®Google Scholar